Abstract

Small cell lung cancer (SCLC) is heterogenous in phenotype and microenvironment. Dynamic phenotypic reprogramming, leading to heterogeneity, is prevalent in SCLC, while the mechanisms remain incompletely understood. Cancer-associated fibroblasts (CAFs) possess comprehensive roles in cancer progression, while their function in phenotypic reprogramming of SCLC remain elusive. Here, we obtained transcriptome data of SCLC tissues from publicly available databases, subsequently estimated abundance of CAFs. We found CAF-abundant SCLC exhibited non-neuroendocrine (Non-NE) characteristics. Supporting this, the positive correlation of expression level of α-SMA, the CAF marker, and expression level of REST, protein typically expressed in Non-NE type SCLC, was identified in SCLC tissue arrays. Moreover, we revealed that fibroblasts inhibited NE markers expression and cell proliferation of SCLC cells in the co-culture system comprising lung fibroblasts and SCLC cells, indicating a phenotypic reprogramming from NE to Non-NE. During this process, fibroblast-derived IL-6 activated the JAK2/STAT3 signaling, upregulated c-MYC expression, and subsequently activated the NOTCH pathway, driving phenotypic reprogramming. Moreover, CAF-enriched SCLC exhibited increased immune cell infiltration, elevated expression of immune activation-related signatures, and checkpoint molecules. Our data also highlighted the chemoresistance induced by fibroblasts in SCLC cells, which was effectively reversed by JAK inhibitor. In conclusion, fibroblasts induced phenotypic reprogramming of SCLC cells from NE to Non-NE, likely contributes to inflamed immune microenvironment and chemoresistance. These findings provide novel insights into the clinical implications of CAFs in SCLC.

Details

Title
Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer
Author
Lu, Yuanhua 1 ; Li, Hui 2 ; Zhao, Peiyan 2 ; Tian, Lin 1 ; Liu, Yan 2 ; Sun, XiaoDan 3 ; Cheng, Ying 4 

 Jilin Cancer Hospital, Postdoctoral Research Workstation, Changchun, China (GRID:grid.440230.1) (ISNI:0000 0004 1789 4901) 
 Jilin Cancer Hospital, Medical Oncology Translational Research Lab, Changchun, China (GRID:grid.440230.1) (ISNI:0000 0004 1789 4901) 
 Jilin Cancer Hospital, Department of 1st Gynecologic Oncology Surgery, Changchun, China (GRID:grid.440230.1) (ISNI:0000 0004 1789 4901) 
 Jilin Cancer Hospital, Medical Oncology Translational Research Lab, Changchun, China (GRID:grid.440230.1) (ISNI:0000 0004 1789 4901); Jilin Cancer Hospital, Department of Medical Thoracic Oncology, Changchun, China (GRID:grid.440230.1) (ISNI:0000 0004 1789 4901) 
Pages
2884
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2921814275
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.